ProQR Therapeutics (NASDAQ:PRQR) Issues Earnings Results

ProQR Therapeutics (NASDAQ:PRQR) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02), Zacks reports. ProQR Therapeutics had a negative net margin of 273.20% and a negative return on equity of 55.54%. The firm had revenue of $3.38 million during the quarter, compared to analyst estimates of $7.05 million.

ProQR Therapeutics Price Performance

Shares of PRQR stock traded up $0.01 on Friday, hitting $2.22. 526,627 shares of the company’s stock were exchanged, compared to its average volume of 600,782. The company has a 50 day moving average of $2.40 and a 200 day moving average of $2.11. The stock has a market cap of $233.57 million, a P/E ratio of -4.72 and a beta of 0.16. ProQR Therapeutics has a 12 month low of $1.07 and a 12 month high of $4.21.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in PRQR. BNP Paribas Financial Markets boosted its position in ProQR Therapeutics by 28.4% in the second quarter. BNP Paribas Financial Markets now owns 121,494 shares of the biopharmaceutical company’s stock valued at $248,000 after buying an additional 26,893 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of ProQR Therapeutics by 25.7% in the 2nd quarter. Bank of America Corp DE now owns 119,198 shares of the biopharmaceutical company’s stock valued at $243,000 after purchasing an additional 24,347 shares during the last quarter. Jane Street Group LLC boosted its position in ProQR Therapeutics by 699.3% during the first quarter. Jane Street Group LLC now owns 91,120 shares of the biopharmaceutical company’s stock valued at $121,000 after acquiring an additional 79,720 shares during the last quarter. Finally, Osaic Holdings Inc. grew its stake in ProQR Therapeutics by 59.6% during the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 4,500 shares during the period. Institutional investors own 32.65% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on PRQR. Chardan Capital reissued a “buy” rating and set a $4.00 price target on shares of ProQR Therapeutics in a research report on Tuesday. Evercore ISI reissued an “outperform” rating on shares of ProQR Therapeutics in a report on Friday, July 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ProQR Therapeutics in a report on Wednesday, October 8th. Finally, Zacks Research cut ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 15th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $7.14.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).